Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Sutro Biopharma Inc (STRO)

Sutro Biopharma Inc (STRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Wed Jan 7, 3:05PM CST

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

STRO : 13.82 (+5.74%)
Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement GlobeNewswire - Wed Dec 17, 2025

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

STRO : 13.82 (+5.74%)
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue Dec 16, 2025

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format...

STRO : 13.82 (+5.74%)
Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors GlobeNewswire - Wed Dec 3, 2025

– Initial clinical data expected mid-2026 – SOUTH SAN FRANCISCO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology...

STRO : 13.82 (+5.74%)
Sutro Biopharma Announces 1-for-10 Reverse Stock Split GlobeNewswire - Mon Dec 1, 2025

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format...

STRO : 13.82 (+5.74%)
Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day GlobeNewswire - Wed Nov 12, 2025

- Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC -  - Sutro has selected PTK7 as the target for its initial dual-payload candidate, STRO-227 - ...

STRO : 13.82 (+5.74%)
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights GlobeNewswire - Thu Nov 6, 2025

– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; Expects to dose first patient before year-end – ...

STRO : 13.82 (+5.74%)
Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025 GlobeNewswire - Wed Nov 5, 2025

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug...

STRO : 13.82 (+5.74%)
Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference GlobeNewswire - Mon Nov 3, 2025

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug...

STRO : 13.82 (+5.74%)
Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones GlobeNewswire - Mon Sep 29, 2025

– Extends cash runway into at least mid-2027 – SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company...

STRO : 13.82 (+5.74%)

Barchart Exclusives

Rising Crypto Sentiment Could Make Cipher Mining (CIFR) a Strong Bullish Options Trade Barchart - Mon Jan 19, 12:30PM CST
With digital assets apparently poised to make a comeback, blockchain mining investment CIFR stock offers an intriguing platform for speculation. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot